A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis

International Journal of Infectious Diseases

Volumn 16, Issue 12, 2012, Pages

  Monmaturapoj, Teerapong ^a   Montakantikul, Preecha ^a   Mootsikapun, Piroon ^b   Tragulpiankit, Pramote ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Acute pyelonephritis; Cefditoren pivoxil; Escherichia coli; Switch therapy; Urinary tract infection

Indexed keywords

CEFDITOREN PIVOXIL; CEFTRIAXONE; CIPROFLOXACIN; PLACEBO;

ACUTE PYELONEPHRITIS; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT SATISFACTION; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS;

ACUTE DISEASE; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEPHALOSPORINS; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYELONEPHRITIS; TREATMENT OUTCOME;

EID: 84869220819     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.07.009     Document Type: Article

References (27)

1. Foxman B., Ki M., Brown P. Antibiotic resistance and pyelonephritis. Clin Infect Dis 2007, 45:281-283.
2. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaefer A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999, 29:745-758.
3. Kyriakidou K.G., Rafailidis P., Matthaiou D.K., Athanasiou S., Falagas M.E. Short-versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. Clin Ther 2008, 30:1859-1868.
4. Talan D.A., Stamm W.E., Hooton T.M., Moran G.J., Burke T., Iravani A., et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000, 283:1583-1590.
5. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52:103-120.
6. Johnson L., Sabel A., Burman W.J., Everhart R., Rome M., Mackenzie T.D., et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008, 121:876-884.
7. Gaglitti C., Buttazzi R., Sforza S., Moro M.L., Romagna E. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. J Infect 2008, 57:179-184.
8. National Institute of Health (Internet). Nonthaburi; 2010 (cited 2012 Feb 20). National Antimicrobial Resistance Surveillance Center of Thailand. Available from: http://narst.dmsc.moph.go.th/a8.php.
9. Karlowsky J.A., Hoban D.J., Decorby M.R., Laing N.M., Zhanel G. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. Antimicrob Agents Chemother 2006, 50:2251-2254.
10. Ramakrishnan K., Scheid D.C. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician 2005, 71:933-942.
11. Sanchez M., Collvinent B., Miro O., Horcajada J.P., Moreno A., Marco F., et al. Short term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomized controlled trial. Emerg Med J 2002, 19:19-22.
12. Wells W.G., Woods G.L., Jiang Q., Gesser R.M. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004, 53:67-74.
13. Sadaba B., Azanza J.R., Quetglas E.G., Campanero M.A., Honorato J., Coronel P., et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Rev Esp Quimioterap 2007, 20:51-60.
14. Cuevas O., Cercenado E., Gimeno M., Marin M., Coronel P., Bouza E. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. Diagn Microbiol Infect Dis 2010, 67:251-260.
15. Ko K.S., Suh J.Y., Lee M.Y., Lee N.Y., Peck K.R., Kwon K.T., et al. In vitro activity of cefditoren against clinical isolates of Escherichia coli from a Korean hospital. Int J Antimicrob Agents 2007, 30:283-285.
16. Jones R.N., Biedenbach D.J., Johnson D.M. Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagn Microbiol Infect Dis 2000, 37:143-146.
17. Sevillano D., Aguilar L., Alou L., Gimenez M.J., Torrico M., Gonzalez N., et al. Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil. Antimicrob Agents Chemother 2008, 52:1184-1186.
18. Ahkee S., Smith S., Newman D., Ritter W., Burke J., Ramirez J.A. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-months prospective study. Pharmacotherapy 1997, 17:569-575.
19. Wetzstein G.A. Intravenous to oral (IV:PO) anti-infective conversion therapy. Cancer Control 2000, 7:170-176.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
21. Horcajada J.P., Smithson A. Acute pyelonephritis in adults: an update. Rev Med Microbiol 2003, 14:119-127.
22. Suankratay C., Jutivorakool K., Jirajariyavej S. A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria. J Med Assoc Thai 2008, 91:1172-1181.
23. Arslan H., Azap O.K., Ergonul O., Timurkaynak F. Risk factor for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infection in Turkey. J Antimicrob Chemother 2005, 56:914-918.
24. Colodner R., Kometiana I., Chazan B., Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection 2008, 36:41-45.
25. Caron F., Galperine T., Dumarcet N., Azria R., Bingen E., Botto H., et al. Recommendation for good practice guideline for diagnosis and treatment of adult patients with community acquired bacterial urinary tract infection. Med Mal Infect 2009, 39:288-305.
26. Aarakawa S., Kamidono S., Oshi M., Aso Y., Naide Y., Suzuki K., et al. A double-blind comparative study of ME1207 and cefteram pivoxil for the treatment of complicated urinary tract infections. Nishinihon J Urol 1992, 54:1418-1434.
27. Yamauchi D., Kawahara M., Goto T., Obama Y., Kodama M., Yagi S., et al. Antimicrobial activity and clinical study on ME1207 in urinary tract infections. Chemotherapy 1992, 40:536-542.